Stopping Versus Continuing Metformin in Patients With Advanced CKD: A Nationwide Scottish Target Trial Emulation Study

Current guidance recommends against the use of metformin in people with advanced kidney impairment despite a lack of evidence. It is therefore currently unclear how the decision to stop versus continue metformin in patients who reach stage 4 CKD impacts their risk of mortality and cardiovascular events. This study showed that stopping metformin after reaching stage 4 CKD was associated with reduced survival that did not appear to be mediated by an increase in adverse cardiovascular outcomes. These findings may support the continued use of metformin in patients with advanced kidney impairment, but further research is needed to confirm these observations.

Authors

Institutions

Publication Details

Journal
American Journal of Kidney Diseases
Published
2024-11-07
DOI
https://doi.org/10.1053/j.ajkd.2024.08.012
Citations
5
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
1.79

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Stopping Versus Continuing Metformin in Patients With Advanced CKD: A Nationwide Scottish Target Trial Emulation Study

Helen M. Colhoun, Emilie Lambourg, Edouard L. Fu, Alistair Emslie‐Smith et al.
5 citations
American Journal of Kidney Diseases
Diabetes Treatment and Management
1.79
article

Stopping Versus Continuing Metformin in Patients With Advanced CKD: A Nationwide Scottish Target Trial Emulation Study

Helen M. Colhoun, Emilie Lambourg, Edouard L. Fu, Alistair Emslie‐Smith, Patrick Barry Mark, Christopher H. Grant, Rory J. McCrimmon, Brian McKinstry, John McKnight, Robert S. Lindsay, Sandra MacRury, Stuart J. McGurnaghan, John R. Petrie, Samira Bell, Neeraj Dhaun, Ewan R. Pearson, Bryan R. Conway, Catherine Armstrong, Donald Pearson
article en
5 citations

Abstract

Current guidance recommends against the use of metformin in people with advanced kidney impairment despite a lack of evidence. It is therefore currently unclear how the decision to stop versus continue metformin in patients who reach stage 4 CKD impacts their risk of mortality and cardiovascular events. This study showed that stopping metformin after reaching stage 4 CKD was associated with reduced survival that did not appear to be mediated by an increase in adverse cardiovascular outcomes. These findings may support the continued use of metformin in patients with advanced kidney impairment, but further research is needed to confirm these observations.

American Journal of Kidney DiseasesVol. 85(2)
Brigham and Women's Hospital (US), Harvard University (US), University of Dundee (GB), Leiden University Medical Center (NL), Genomics (United Kingdom) (GB), Institute of Genetics and Cancer (GB), University of Glasgow (GB), University of Edinburgh (GB)
University of Dundee, Wellcome Trust
Good health and well-being
Openalex Percentile: Top 13%
Diabetes Treatment and Management
1.79
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.